QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)

Compare Stocks

Date Range: 

 AvantorBio-Rad LaboratoriesWatersPerkinElmer
SymbolNYSE:AVTRNYSE:BIONYSE:WATNYSE:PKI
Price Information
Current Price$39.51$752.37$344.10$185.57
50-Day Moving Average$39.12$748.72$348.30$176.80
52-Week Low$26.14$537.12$235.44$119.95
52-Week High$44.37$832.70$428.22$192.00
MarketRank™
Overall Score2.52.31.72.4
Analysis Score3.51.51.11.5
Community Score5.04.43.94.4
Dividend Score0.00.00.01.7
Ownership Score2.54.22.52.5
Earnings & Valuation Score1.31.31.31.9
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuy
Consensus Price Target$45.19$801.67$367.00$155.31
% Upside from Price Target14.37% upside6.55% upside6.66% upside-16.31% downside
Trade Information
Market Cap$24.08 billion$22.51 billion$21.00 billion$23.42 billion
Beta1.60.880.841.07
Average Volume4,034,136148,261370,770840,565
Sales & Book Value
Annual Revenue$6.39 billion$2.55 billion$2.37 billion$3.78 billion
Price / Sales3.778.848.886.19
Cashflow$1.74 per share$10.69 per share$11.47 per share$10.90 per share
Price / Cash22.7270.3930.0117.03
Book Value$5.09 per share$512.48 per share$4.84 per share$55.14 per share
Price / Book7.761.4771.103.37
Profitability
Net Income$116.60 million$3.81 billion$521.57 million$727.89 million
EPS$0.79$220.47$11.15$10.05
Trailing P/E Ratio50.013.4130.8618.46
Forward P/E Ratio25.8259.9529.3129.27
P/E Growth1.18N/A3.050.38
Net Margins7.07%223.47%25.40%22.41%
Return on Equity (ROE)39.88%4.19%271.71%30.57%
Return on Assets (ROA)7.92%3.21%22.73%14.34%
Dividend
Annual PayoutN/AN/AN/A$0.28
Dividend YieldN/AN/AN/A0.15%
Three-Year Dividend GrowthN/AN/AN/AN/A
Payout RatioN/AN/AN/A2.79%
Years of Consecutive Dividend GrowthN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.79N/A5.470.73
Current Ratio2.703.792.471.97
Quick Ratio2.062.891.891.40
Ownership Information
Institutional Ownership Percentage90.91%64.08%87.69%92.85%
Insider Ownership Percentage2.00%27.67%1.10%0.55%
Miscellaneous
Employees12,4008,0007,40014,000
Shares Outstanding609.45 million29.92 million61.04 million126.20 million
Next Earnings Date2/2/2022 (Estimated)2/10/2022 (Estimated)2/1/2022 (Estimated)2/1/2022 (Estimated)
OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay for Early Detection of Tissue Injury and Prevention of Organ Rejection - Crossville ChroniclePure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay for Early Detection of Tissue Injury and Prevention of Organ Rejection - Crossville Chronicle
crossville-chronicle.com - December 7 at 8:03 AM
Digital Pathology Market will generate new growth opportunities 2021-2028 | Perkin Elmer, Definiens AG, Sectra - EIN NewsDigital Pathology Market will generate new growth opportunities 2021-2028 | Perkin Elmer, Definiens AG, Sectra - EIN News
einnews.com - December 7 at 8:03 AM
Lab Experts Criticize State’s Response To Risk Of ‘Serious Injury, Harm or Death’ At CA COVID Testing Lab - CBS SacramentoLab Experts Criticize State’s Response To Risk Of ‘Serious Injury, Harm or Death’ At CA COVID Testing Lab - CBS Sacramento
sacramento.cbslocal.com - December 7 at 8:03 AM
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market Research Report 2022-2026 - ResearchAndMarkets.com - Business WireGlobal Chemiluminescence Immunoassay (CLIA) Analyzers Market Research Report 2022-2026 - ResearchAndMarkets.com - Business Wire
businesswire.com - December 6 at 5:02 PM
Lab Experts Criticize State’s Response To Risk Of ‘Serious Injury, Harm or Death’ At CA COVID Testing Lab - Good Day SacramentoLab Experts Criticize State’s Response To Risk Of ‘Serious Injury, Harm or Death’ At CA COVID Testing Lab - Good Day Sacramento
gooddaysacramento.cbslocal.com - December 5 at 8:54 PM
Is PerkinElmer, Inc. (PKI) a Winner in the Healthcare Sector? - InvestorsObserverIs PerkinElmer, Inc. (PKI) a Winner in the Healthcare Sector? - InvestorsObserver
investorsobserver.com - December 5 at 3:53 PM
Global Micro Computed Tomography Market By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027 - Yahoo FinanceGlobal Micro Computed Tomography Market By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027 - Yahoo Finance
finance.yahoo.com - December 3 at 10:05 AM
Cord Blood Banking Services Market May See Big Move | PerkinElmer, CBR Systems, Virgin Group – UK Parents Lounge - UK Parents LoungeCord Blood Banking Services Market May See Big Move | PerkinElmer, CBR Systems, Virgin Group – UK Parents Lounge - UK Parents Lounge
ukparentslounge.com - December 3 at 10:05 AM
PerkinElmer (PKI) Up 6.4% Since Last Earnings Report: Can It Continue? - NasdaqPerkinElmer (PKI) Up 6.4% Since Last Earnings Report: Can It Continue? - Nasdaq
nasdaq.com - December 2 at 1:51 PM
PerkinElmer (PKI) Up 6.4% Since Last Earnings Report: Can It Continue?PerkinElmer (PKI) Up 6.4% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - December 2 at 1:51 PM
Investors in PerkinElmer (NYSE:PKI) have made a stellar return of 255% over the past five years - NasdaqInvestors in PerkinElmer (NYSE:PKI) have made a stellar return of 255% over the past five years - Nasdaq
nasdaq.com - December 1 at 2:29 PM
Stock on Demand This Week: PerkinElmer Inc. (PKI) - The Fosters LeaderStock on Demand This Week: PerkinElmer Inc. (PKI) - The Fosters Leader
fostersleader.com - December 1 at 9:29 AM
COVID-19 test makers say their products also detect Omnicron - Medical Design & OutsourcingCOVID-19 test makers say their products also detect Omnicron - Medical Design & Outsourcing
medicaldesignandoutsourcing.com - November 30 at 1:09 PM
With omicron, local diagnostics makers work to ensure their tests work - Boston Business JournalWith omicron, local diagnostics makers work to ensure their tests work - Boston Business Journal
bizjournals.com - November 30 at 7:44 AM
Gilead Chooses AWS, Illumina, Sequoia Fund Chinese Startups, More - Bio-IT WorldGilead Chooses AWS, Illumina, Sequoia Fund Chinese Startups, More - Bio-IT World
bio-itworld.com - November 30 at 1:24 AM
PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability of its RT-PCR Assays - Business WirePerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability of its RT-PCR Assays - Business Wire
businesswire.com - November 29 at 8:23 PM
Is PerkinElmer Inc. (NYSE: PKI) Worth It? How Should Investors Deal With It?Is PerkinElmer Inc. (NYSE: PKI) Worth It? How Should Investors Deal With It?
marketingsentinel.com - November 29 at 10:23 AM
PerkinElmer (NYSE:PKI) Shares Up 5%PerkinElmer (NYSE:PKI) Shares Up 5%
americanbankingnews.com - November 26 at 12:15 PM
Is PerkinElmer, Inc. (PKI) Stock a Smart Value Tuesday? - InvestorsObserverIs PerkinElmer, Inc. (PKI) Stock a Smart Value Tuesday? - InvestorsObserver
investorsobserver.com - November 23 at 11:00 PM
No consequences for PerkinElmer following CDPH investigation into COVID-19 testing lab - FOX40No consequences for PerkinElmer following CDPH investigation into COVID-19 testing lab - FOX40
fox40.com - November 23 at 11:00 PM
PerkinElmer (NYSE:PKI) Shares Gap Down to $188.82PerkinElmer (NYSE:PKI) Shares Gap Down to $188.82
americanbankingnews.com - November 23 at 11:40 AM
California officials release long-awaited report on troubled state testing lab - Santa Rosa Press DemocratCalifornia officials release long-awaited report on troubled state testing lab - Santa Rosa Press Democrat
pressdemocrat.com - November 23 at 1:26 AM
California officials release report on troubled state lab - Los Angeles TimesCalifornia officials release report on troubled state lab - Los Angeles Times
latimes.com - November 22 at 8:26 PM
Liontrust Investment Partners - GuruFocus.comLiontrust Investment Partners - GuruFocus.com
gurufocus.com - November 22 at 10:24 AM
PerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management - Business WirePerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management - Business Wire
businesswire.com - November 22 at 10:24 AM
DateCompanyBrokerageAction
11/22/2021AvantorJPMorgan Chase & Co.
Initiated Coverage
11/17/2021PerkinElmerRoyal Bank of Canada
Boost Price Target
11/3/2021PerkinElmerWells Fargo & Company
Boost Price Target
11/3/2021PerkinElmerRobert W. Baird
Boost Price Target
11/1/2021AvantorRaymond James
Boost Price Target
11/1/2021AvantorThe Goldman Sachs Group
Reiterated Rating
11/1/2021AvantorCitigroup
Boost Price Target
11/1/2021AvantorRobert W. Baird
Boost Price Target
11/1/2021AvantorBarclays
Boost Price Target
10/14/2021AvantorCowen
Lower Price Target
9/10/2021AvantorStifel Nicolaus
Boost Price Target
9/10/2021AvantorCredit Suisse Group
Boost Price Target
9/9/2021AvantorKeyCorp
Boost Price Target
8/30/2021AvantorRaymond James
Initiated Coverage
8/9/2021PerkinElmerRoyal Bank of Canada
Boost Price Target
8/4/2021WatersSVB Leerink
Boost Price Target
8/4/2021WatersRobert W. Baird
Boost Price Target
8/4/2021WatersCitigroup
Boost Price Target
8/2/2021AvantorTruist Securities
Boost Price Target
8/2/2021AvantorMorgan Stanley
Boost Price Target
8/2/2021AvantorTruist
Boost Price Target
8/2/2021AvantorCitigroup
Boost Price Target
8/2/2021AvantorBarclays
Boost Price Target
8/2/2021AvantorPiper Sandler
Upgrade
7/30/2021AvantorCredit Suisse Group
Boost Price Target
7/30/2021AvantorWells Fargo & Company
Boost Price Target
7/30/2021AvantorKeyCorp
Boost Price Target
7/30/2021Bio-Rad LaboratoriesWells Fargo & Company
Boost Price Target
7/27/2021PerkinElmerEvercore ISI
Reiterated Rating
7/27/2021PerkinElmerRobert W. Baird
Reiterated Rating
7/6/2021WatersEvercore ISI
Upgrade
6/15/2021PerkinElmerWolfe Research
Upgrade
6/4/2021AvantorThe Goldman Sachs Group
Initiated Coverage
5/6/2021WatersSVB Leerink
Boost Price Target
5/6/2021WatersWells Fargo & Company
Boost Price Target
4/29/2021AvantorCredit Suisse Group
Boost Price Target
4/29/2021AvantorRaymond James
Boost Price Target
4/29/2021AvantorMorgan Stanley
Boost Price Target
4/29/2021AvantorJPMorgan Chase & Co.
Boost Price Target
2/12/2021Bio-Rad LaboratoriesCitigroup
Boost Price Target
2/5/2021Bio-Rad LaboratoriesJefferies Financial Group
Boost Price Target
2/3/2021WatersCitigroup
Boost Price Target
2/3/2021PerkinElmerCitigroup
Boost Price Target
1/7/2021WatersWells Fargo & Company
Downgrade
1/7/2021PerkinElmerWells Fargo & Company
Upgrade
12/17/2020WatersCleveland Research
Upgrade
12/16/2020WatersSmith Barney Citigroup
Upgrade
12/11/2020PerkinElmerSmith Barney Citigroup
Boost Price Target
12/2/2020WatersThe Goldman Sachs Group
Initiated Coverage
12/2/2020PerkinElmerThe Goldman Sachs Group
Initiated Coverage
11/12/2020PerkinElmerThe Goldman Sachs Group
Initiated Coverage
11/9/2020WatersKeyCorp
Initiated Coverage
11/9/2020PerkinElmerKeyCorp
Initiated Coverage
11/9/2020PerkinElmerNeedham & Company LLC
Boost Price Target
10/30/2020Bio-Rad LaboratoriesSmith Barney Citigroup
Boost Price Target
10/30/2020Bio-Rad LaboratoriesWells Fargo & Company
Boost Price Target
10/29/2020PerkinElmerSmith Barney Citigroup
Boost Price Target
10/29/2020PerkinElmerWells Fargo & Company
Boost Price Target
10/29/2020PerkinElmerRobert W. Baird
Boost Price Target
10/28/2020WatersStifel Nicolaus
Boost Price Target
10/28/2020WatersSmith Barney Citigroup
Boost Price Target
10/28/2020WatersWells Fargo & Company
Boost Price Target
10/28/2020WatersSVB Leerink
Boost Price Target
9/11/2020PerkinElmerNeedham & Company LLC
Upgrade
9/3/2020Bio-Rad LaboratoriesJefferies Financial Group
Reiterated Rating
9/3/2020Bio-Rad LaboratoriesWells Fargo & Company
Reiterated Rating
8/10/2020PerkinElmerBMO Capital Markets
Boost Price Target
7/31/2020Bio-Rad LaboratoriesWells Fargo & Company
Boost Price Target
7/31/2020Bio-Rad LaboratoriesCitigroup
Boost Price Target
7/30/2020Bio-Rad LaboratoriesWells Fargo & Company
Reiterated Rating
7/29/2020WatersStifel Nicolaus
Boost Price Target
7/29/2020WatersSVB Leerink
Boost Price Target
7/29/2020WatersCitigroup
Boost Price Target
7/29/2020PerkinElmerJPMorgan Chase & Co.
Boost Price Target
7/29/2020PerkinElmerStifel Nicolaus
Boost Price Target
7/29/2020PerkinElmerWells Fargo & Company
Boost Price Target
7/29/2020PerkinElmerCfra
Upgrade
7/28/2020WatersNeedham & Company LLC
Initiated Coverage
7/28/2020WatersJPMorgan Chase & Co.
Upgrade
7/16/2020WatersWells Fargo & Company
Upgrade
7/13/2020PerkinElmerNeedham & Company LLC
Initiated Coverage
5/21/2020Bio-Rad LaboratoriesWells Fargo & Company
Boost Price Target
5/7/2020Bio-Rad LaboratoriesCitigroup
Boost Price Target
5/7/2020PerkinElmerUBS Group
Boost Price Target
4/29/2020WatersBank of America
Lower Price Target
4/29/2020WatersStifel Nicolaus
Boost Price Target
4/29/2020WatersSVB Leerink
Lower Price Target
4/20/2020Bio-Rad LaboratoriesCitigroup
Boost Price Target
3/30/2020Bio-Rad LaboratoriesWells Fargo & Company
Lower Price Target
3/26/2020Bio-Rad LaboratoriesBarclays
Lower Price Target
3/20/2020Bio-Rad LaboratoriesCitigroup
Lower Price Target
3/3/2020Bio-Rad LaboratoriesCitigroup
Reiterated Rating
2/14/2020Bio-Rad LaboratoriesWells Fargo & Company
Boost Price Target
1/7/2020Bio-Rad LaboratoriesWells Fargo & Company
Initiated Coverage
1/6/2020Bio-Rad LaboratoriesCitigroup
Initiated Coverage
8/20/2019Bio-Rad LaboratoriesThe Goldman Sachs Group
Upgrade
8/2/2019Bio-Rad LaboratoriesBarclays
Boost Price Target
5/9/2019Bio-Rad LaboratoriesDeutsche Bank Aktiengesellschaft
Boost Price Target
5/9/2019Bio-Rad LaboratoriesBarclays
Boost Price Target
3/1/2019Bio-Rad LaboratoriesDeutsche Bank Aktiengesellschaft
Boost Price Target
(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.